The FDA approved a new non-opioid painkiller. Its producer’s stock is rising

Vertex Pharmaceuticals (Vrtx) Stock Rose Friday after Food and Drug Administration (FDA) approved its new painkiller, the first of its kind approved by regulators.

Journal or Suzetrigin, was approved for the treatment of adults with moderate to severe acute pain, which is usually caused by surgery, illness or painful medical procedures. More than 80 million people is prescribed medicine for acute pain every year according to the peak.

The company said that Journavx is the only approved non-OPIOID painkiller and the first new class of pain medicine approved for more than two decades. Its approval comes after years of research and attempts to develop similar drugs as well as the opioid crisis. Estimated 81,806 people died of opioid -related overdoses in 2022, According to Centers for Disease Control.

“With the approval of Journavax, a non-opioid, pain signal inhibitor and the first new class of pain medicine approved in more than 20 years, we have the opportunity to change the paradigm of emergency pain management and establish a new standard for care,” Said Vertex CEO RESHMA KEWALRAMANI IN A declaration.

The Vertex share rose more than 4% in trading before the market on Friday, adding its 8% annual growth.

The FDA has approved Journavax to be taken twice a day for adults, with Vertex noticing that it is not known whether painkillers are safe for children. Verte said it had established a wholesale purchase cost of $ 15.50 per year. 50-MILLRAM pill.

While speaking in 2025 JP Morgan (JPM) Health Conference, Vertex confirmed It is “launching ready” with plans to start selling the drug as soon as it secured the FDA approval, according to Fierce Pharma. The drug is expected to bring in sales of $ 866 million, according to Leerink Partners’ estimates. By 2030, it could bring as much as $ 2.9 billion in sales.

For the latest news, FacebookAt Twitter and Instagram.